ortic stenosis is an age-related disorder that is characterized by calcification of the aortic valve, local lipid accumulation, inflammation, and neo-angiogenesis. 1 Because the aged population is increasing, increased numbers of patients are experiencing aortic stenosis, so the number of patients requiring aortic valve replacement (AVR) is increasing. 2 AVR still remains the standard therapy for symptomatic severe aortic stenosis, although transcatheter aortic valve implantation is considered as an alternative therapy for elderly patients at high risk for perioperative complications. 3 In Asian countries in particular, female and elderly patients with aortic valve stenosis often have a small aortic annulus.
Prosthesis-patient mismatch (PPM) is the difference between the area of the implanted prosthetic valve and that of the patient's native valve without a stenotic lesion. Previous studies have shown that PPM, defined as an effective orifice area index (EOAI ie, effective orifice area divided by body surface area (BSA)) <0.85 cm 2 /m 2 , may negatively affect postoperative clinical status and survival. 4-6 Thus, surgeons need a prospective strategy for selection of the best prosthesis and operative method to prevent PPM.
The 17-mm Regent prosthesis is an option in patients with a small aortic annulus, although there are few reports of midterm outcomes after AVR with a 17-mm prosthesis in large series of patients. Thus, the primary objective of this study was to evaluate mid-term clinical outcomes after AVR with the 17-mm Regent prosthesis and the effect of PPM. Warfarin sodium was started on the day of surgery and continued thereafter so that the international normalized ratio of prothrombin time was maintained in accordance with American College of Cardiology/American Heart Association guidelines. Operative data are shown in Table 1 .
Methods

Patients
Echocardiography
Standard M-mode dimensions were obtained according to the American Society of Echocardiography criteria. The mean of 3 measures from 2 different cardiac cycles was taken. The following variables were obtained: end-diastolic septal thickness, left ventricular end-diastolic dimension, and end-diastolic left ventricular posterior wall thickness. All Doppler measurements were averaged from more than 3 cycles in patients with sinus rhythm and more than 5 cycles in those with atrial fibrillation. Maximum pressure gradients were calculated from the complete Bernoulli equation. Left ventricular mass was calculated according to the Devereux formula. 7 The EOA was determined by the standard continuity equation and indexed to BSA.
Follow-up
Follow-up transthoracic echocardiographic data were obtained for 35 (45%) of the 78 patients at 13.3±10.8 (mean ± SD) months after surgery. The clinical status of each patient was evaluated by means of direct hospital visits and telephone interviews. Follow-up was 100% complete. Mean follow-up was 32.6±19.6 months (range, 5-70 months). A major adverse valve-related event was defined according to the guidelines for reporting after cardiac valve interventions. 8
Statistical Analysis
Data are reported as mean ± SD. Preoperative and postoperative echocardiographic data for all patients were compared and analyzed by paired Student's t-test. Patients were divided into 2 groups: with and those without PPM at discharge. Differences between the groups were analyzed by chi-square test or unpaired Student's t-test as appropriate. Logistic regression was used to identify factors associated with in-hospital death.
Variables were entered into multivariate analysis if univariate analysis yielded a P-value <0.15. Actuarial survival was calculated by the Kaplan-Meier method. A Cox proportional hazards model was used to identify predictors of survival and adverse events. Variables included in the multivariate analysis were those with P-value <0.15 in the univariate analysis.
The log-rank test was used to compare differences in actuarial survival between groups. All analyses were performed with SPSS software (version 10.1; SPSS, Chicago, IL, USA). P<0.05 was considered significant.
Results
Operative Morbidity and Mortality
Overall hospital mortality was 2.6% (2 patients). The causes of hospital deaths were respiratory failure and intestinal necrosis. Univariate analysis identified renal insufficiency and preoperative dialysis as predictors of hospital mortality. However, multivariate regression analysis yielded no independent predictor of hospital death. One patient required perioperative intra-aortic balloon pumping and percutaneous cardiopulmonary support because of hemodynamic instability. Postoperatively, 1 patient suffered cerebral infarction. None required pacemaker implantation.
Clinical Follow-up and Valve-Related Events
Two patients were readmitted because of heart failure. One patient experienced late cerebral hemorrhage. Cerebral infarction, prosthetic endocarditis, structural failure of the prosthesis, reoperation, and paravalvular leakage did not occur in any patient during the follow-up period. Freedom from major adverse valve-related cardiac events at 1 year, 3 years, and 5 years was 97.3%, 93.9%, and 93.9%, respectively ( Figure 1 ). The linearized rate of valve-related cardiac events was 2.3 per 100 patient-years. Major adverse valve-related cardiac events are summarized in Table 2 . Univariate analysis revealed that Functional NYHA Class Before Surgery and at Follow-up All patients except the 2 who died in the hospital were assessed for physical capacity according to NYHA classification during follow-up: 75 patients (99%) improved to class II or better after AVR. 
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Echocardiographic Variables
Preoperative echocardiography yielded a mean aortic valve area index of 0.41±0.13 cm 2 /m 2 , a mean left ventricular-aortic pressure gradient (LVAo-PG) of 59.0±21.5 mmHg, and a mean left ventricular mass index (LVMI) of 175±53 g/m 2 . Follow-up echocardiography revealed a significant decrease in mean LVAo-PG (16.6±6.8 mmHg), a significant decrease in LVMI (116±32 g/m 2 ), and a significant increase in mean EOAI (0.97±0.21 cm 2 /m 2 ). There was no significant difference between the preoperative and postoperative ejection fractions (0.60±0.14 vs. 0.63±0.07).
Effect of PPM on Long-Term Survival and Echocardiographic Variables
The EOA was obtained at discharge for 58 (74%) of 78 patients. Of these 58 patients, 18 (31%) had PPM with an Figure 3 . Reduction in LVMI as well as LVAo-PG at follow-up did not differ between the 2 groups. Neither was there a difference in long-term survival between the 2 groups ( Figure 4 ).
Discussion
Elderly Japanese are shorter in stature than their Western counterparts, and the aortic annulus of the Japanese is smaller, proportionate to their body size. Therefore, we often need a strategy to deal with the problem of a small annulus. The EOAI, which correlates with the postoperative transvalvular gradient, has been used to characterize PPM. On the basis of the relation between the EOAI and corresponding gradient, Pibarot et al reported that the ideal EOAI should exceed 0.85 cm 2 /m 2 to avoid a residual pressure gradient. 5,9 Thus, in the case of patients with a small aortic annulus, careful evaluation is needed to achieve an EOAI >0.85 cm 2 /m 2 after AVR surgery because PPM may predispose to an unfavorable outcome. 4-6
The main consequence of PPM is generation of an abnormally high transprosthetic gradient across the aortic valve, resulting in increased left ventricular work. Incomplete regression of the residual gradient across the prosthesis has been associated with increased long-term mortality. 10 The decrease in the LVMI is considered to be a result of favorable remodeling derived from AVR. PPM is also associated with a smaller decrease in the LVMI and more cardiac events during the fol-low-up period. 11, 12 Prevention of PPM has also been reported to improve postoperative functional class/exercise tolerance and the incidence of late sudden death. 6,13 However, some investigators have reported that the influence of PPM on outcome after AVR surgery remains controversial. 11,14- 16 Various surgical strategies, such as aortic root enlargement and stentless valve implantation, have been used to avoid PPM. Enlargement of the aortic annulus is based on the premise that a large-sized prosthesis favorably influences late clinical outcome. 17 Castro et al performed aortic root enlargement procedures in 114 patients to avoid PPM. 18 However, aortic annulus enlargement has been shown to result in prolonged aortic cross-clamp times. In addition, recent advances in the design of prostheses have improved hemodynamic performance considerably. Therefore, we choose to forgo annular enlargement in favor of implantation of a high-performance mechanical valve for patients with a small aortic annulus. Supra-annular implantation of a larger valve is considered a feasible option in some institutions. However, because the subvalvular tissue is in close proximity to the prosthetic orifice when the valve is implanted in the supra-annular position, protrusion of subvalvular tissue into the prosthetic orifice, which can lead to valve dysfunction, is of concern, especially in AVR with a mechanical valve. Therefore, we generally use intra-annular positioning for implantation of a mechanical valve. The 17-mm St. Jude Medical Regent valve with an EOA of 1.30 cm 2 can be used in patients with a BSA <1.5 m 2 , resulting in an EOAI >0.85 cm 2 /m 2 .
Only a few authors have reported their experience with a 17-mm mechanical prosthesis, and controversy remains as to whether this valve is beneficial and safe, especially in the long term. Previously, we reported good hemodynamics and a 38% decrease in LVMI after AVR with a 17-mm Regent valve, as well as favorable clinical status. 19 Other groups have shown satisfactory clinical improvement and significant left ventricular mass regression after AVR with a 17-mm mechanical prosthesis. 20, 21 These findings suggest that implantation of a 17-mm Regent valve provides not only excellent operative results but also good survival, associated with the better hemodynamic results. Minardi et al reported satisfactory hemodynamic performance in 19 patients with the 17-mm Regent valve under dobutamine stress as well as at rest. 22 Garatti et al also showed good early and long-term outcomes after AVR with a 17-mm mechanical valve, although their evaluation included only the 17-mm Sorin Bicarbon Slim prosthesis (Sorin Biomedica, Saluggia, Italy), and the 17-mm St. Jude Medical Hemodynamic Plus (St. Jude Medical). 23 It must be noted that the follow-up periods were relatively short and the number of patients in each study was small. So, we need to look more carefully into the safety and effectiveness of the 17-mm valve in a large number of patients.
The drawback of a mechanical valve is lifelong anticoagulation, and close monitoring is required to prevent postoperative complications, including thromboembolism and anticoagulation-related bleeding. Some could argue that mechanical valves (vs. bioprostheses) will increase mortality and morbidity as a result of anticoagulation. 24 However, in our series, we encountered cerebral hemorrhage in 2 patients, accounting for a linearized rate of 0.5% per patient-year, but no cerebral infarction. These complication rates are comparable to those of patients given a bioprosthesis. Aupart et al studied clinical outcomes of AVR in 1,133 patients who received a bioprosthesis and reported a bleeding complication rate of 0.3% per patient-year and thromboembolism rate of 0.6% per patientyear. 25 Despite the need for lifelong anticoagulation in patients who receive a mechanical prosthesis, some reports have indicated no significant differences in postoperative quality of life, survival, or incidence of complications between mechanical and biological valves. 26 The effect of PPM on prognosis and cardiac function remains controversial. Mohty et al indicated that PPM negatively influences long-term survival in specific patient groups such as those with low cardiac function or severe PPM. 27 Moon et al reported that PPM had a negative impact on longterm survival only for patients 70 years of age or less. 28 Vicchio et al showed that in patients over age 70, severe or moderate PPM did not influence long-term outcome, left ventricular mass regression or quality of life. 29 In our series, there was no difference in survival or reduction in LVMI between patients with and without PPM, although the incidence of severe PPM was low. Also, our study included only a small number of patients with low cardiac function or severe PPM.
Another mechanical valve currently available for a small aortic annulus is the 16-mm ATS-Advanced Performance valve (ATS Medical, Inc, Minneapolis, MN, USA). Kobayashi et al reported on 15 patients in whom the 16-mm valve was implanted. 30 There was no in-hospital mortality or significant postoperative reduction of LVMI despite a high incidence of PPM. However, some of their patients given the 16-mm valve showed no improvement in left ventricular diastolic function at mid-term follow-up.
Study Limitations
The limitations of our study should be taken into consideration. The main limitation is the relatively low echocardiographic follow-up rate. Most of our patients were followed up at another hospital or clinic, some of which were far from the hospital where the operation was performed. In addition, the study group comprised mostly elderly patients. Nearly half of the patients were unable to return for echocardiographic assessment. Whether or to what degree this low follow-up rate affected our survival and LVMI regression data is unknown. Furthermore, the low incidence of severe PPM in our series might have obscured the potential affect of PPM on outcomes.
Conclusions
In summary, the 17-mm Regent prosthesis produced satisfactory results in terms of survival, physical capacity, and hemodynamic performance. Thus, the 17-mm prosthesis could be a reasonable alternative, especially in patients with a small aortic annulus. Although we confirmed the safety and effectiveness of the prosthesis over 33 months of follow-up, we need to evaluate outcomes over a longer period and in a substantially large study group.
